SEOUL, South Korea, November 10, 2010 /PRNewswire/ -- Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented today the summary results of a retrospective clinical study of human embryonic stem cell (hESC) therapy in patients with chronic spinal cord injury (SCI). Speaking at the 2nd Annual World Stem Cells & Regenerative Medicine Congress Asia 2010, Dr. Shroff explained her treatment protocol and clinical results, demonstrating the safety and efficacy of her human embryonic stem cell (hESC) therapy. The groundbreaking study was conducted on 108 chronic SCI patients treated by Dr. Shroff over a 6 year period-2004 to 2009. Dr Geeta Shroff also shared her vision, which is to see hESC therapy available globally as the first line of treatment for many of mankind's worst afflictions and her willingness to collaborate with entities and work with regulatory authorities worldwide, to realise this vision.
About the hESC Technology
Dr. Geeta Shroff has developed a commercially viable technology to isolate hESC, culture them, prepare them for clinical application and store them in ready-to-use form with a shelf life of six months. This technology, which has patents applied for worldwide, provides a safe and effective, 'purely human' product, for the treatment of a wide range of medical conditions. The ready-to-use product is universally acceptable as it does not require any cross- matching and has a shelf life of 6 months, making it amenable to global marketing. The technology is being used clinically to treat many conditions including spinal injuries, multiple sclerosis, Parkinson's disease, diabetes, Lyme disease, cerebral palsy and autism. Since 2002, more than 800 patients from 35 countries have been treated at Nutech Mediworld, New Delhi and the number is steadily growing.
For further information, please contact: Nutech Mediworld firstname.lastname@example.org
|SOURCE Nutech Mediworld|
Copyright©2010 PR Newswire.
All rights reserved